Tom Hsun-Wei Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1063205/publications.pdf

Version: 2024-02-01

20 papers 1,619 citations

16 h-index 752698 20 g-index

20 all docs

20 docs citations

times ranked

20

2184 citing authors

#	Article	IF	CITATIONS
1	An overview on biological mechanisms of PPARs. Pharmacological Research, 2005, 51, 85-94.	7.1	580
2	Chemistry and Pharmacology of Gynostemma pentaphyllum. Phytochemistry Reviews, 2005, 4, 197-219.	6.5	132
3	Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids. British Journal of Pharmacology, 2005, 145, 767-774.	5.4	120
4	Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-I ^o B activation. Journal of Ethnopharmacology, 2006, 104, 149-155.	4.1	99
5	Herbal or Natural Medicines as Modulators of Peroxisome Proliferator-Activated Receptors and Related Nuclear Receptors for Therapy of Metabolic Syndrome. Basic and Clinical Pharmacology and Toxicology, 2005, 96, 3-14.	2.5	92
6	Salacia root, a unique Ayurvedic medicine, meets multiple targets in diabetes and obesity. Life Sciences, 2008, 82, 1045-1049.	4.3	80
7	Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: Activation of PPAR-α. Toxicology and Applied Pharmacology, 2006, 210, 225-235.	2.8	75
8	A novel LXR- $\hat{l}\pm$ activator identified from the natural product Gynostemma pentaphyllum. Biochemical Pharmacology, 2005, 70, 1298-1308.	4.4	62
9	Salacia oblonga root improves cardiac lipid metabolism in Zucker diabetic fatty rats: Modulation of cardiac PPAR-l±-mediated transcription of fatty acid metabolic genes. Toxicology and Applied Pharmacology, 2006, 210, 78-85.	2.8	62
10	Salacia oblonga improves cardiac fibrosis and inhibits postprandial hyperglycemia in obese zucker rats. Life Sciences, 2004, 75, 1735-1746.	4.3	60
11	Gypenoside XLIX isolated from Gynostemma pentaphyllum inhibits nuclear factor-kappaB activation via a PPAR-alpha-dependent pathway. Journal of Biomedical Science, 2006, 13, 535-548.	7.0	53
12	The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacological Research, 2009, 60, 195-206.	7.1	50
13	Gypenoside XLIX, a naturally occurring PPAR-α activator, inhibits cytokine-induced vascular cell adhesion molecule-1 expression and activity in human endothelial cells. European Journal of Pharmacology, 2007, 565, 158-165.	3.5	43
14	The pathophysiological function of peroxisome proliferator-activated receptor- \hat{l}^3 in lung-related diseases. Respiratory Research, 2005, 6, 102.	3.6	34
15	Gypenoside XLIX, a naturally occurring gynosaponin, PPAR-alpha dependently inhibits LPS-induced tissue factor expression and activity in human THP-1 monocytic cells. Toxicology and Applied Pharmacology, 2007, 218, 30-36.	2.8	26
16	Increased renal collagen crossâ€linking and lipid accumulation in nephropathy of Zucker diabetic fatty rats. Diabetes/Metabolism Research and Reviews, 2008, 24, 498-506.	4.0	24
17	Management of Cardiorenal Metabolic Syndrome in Diabetes Mellitus: A Phytotherapeutic Perspective. Journal of Diabetes Research, 2014, 2014, 1-12.	2.3	13
18	Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs). Current Molecular Pharmacology, 2012, 5, 241-247.	1.5	6

#	Article	IF	CITATIONS
19	An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn's Disease. Biologics: Targets and Therapy, 2021, Volume 15, 237-245.	3.2	5
20	In vivo morphologic comparison of saphenous vein grafts and native coronary arteries following non-ST elevation myocardial infarction. Cardiovascular Revascularization Medicine, 2019, 20, 16-21.	0.8	3